The European Medicines Agency is expecting use of its rolling review procedure to increase during the current COVID-19 pandemic and has introduced a corresponding fee for companies using the mechanism.
The new rolling review fee of EUR 148,400 ($166,690) corresponds to half the basic fee for a full marketing authorization...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?